Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziltivekimab versus placebo for cardiovascular outcomes in ASCVD with CKD and systemic inflammation
NL-OMON54148Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD) and chronic inflammation comparing Ziltivekimab with Placebo (2 arms). Started Nov 2021; status: recruiting.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)chronic inflammation
Beyond the preview
Go deeper on NL-OMON54148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54148.